Second-line antituberculosis drugs: Current knowledge, recent research findings and controversies

Antituberculosis Chemotherapy

Volumn 10, Issue , 2011, Pages 81-95

  Simon Schaaf, H ^a,b   Seddon, James A ^a,c   Caminero, Jose A ^d,e  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^e INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925845207     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000324382     Document Type: Chapter

References (105)

1. World Health Organization: Multidrug and Extensively Drug-Resistant TB (M/XDR-TB): 2010 Global Report on Surveillance and Response. WHO/HTM/TB/2010.3. Geneva, WHO, 2010.
2. World Health Organization: Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis-Emergency Update. WHO/HTM/TB/2008.402. Geneva, WHO, 2008.
3. Caminero JA, Sotgiu G, Zumla A, Migliori GB:Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010;10:621-629.
4. Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John MA, Reubenson G, Govindasamy D, Wong M, Padanilam X, Dziwiecki A, van Helden PD, Siwendu S, Jarand J, Menezes CN, Burns A, Victor T, Warren R, Grobusch MP, van der Walt M, Kvasnovsky C: Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010;375:1798-1807.
5. McClatchy JK, Kanes W, Davidson PT, Moulding TS: Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. Tubercle 1977;58:29-34.
6. Tsukamura M: Cross-resistance relationships between capreomycin, kanamycin, and viomycin resistances in tubercle bacilli from patients. Am Rev Respir Dis 1969;99:780-782.
7. Jureen P, Angeby K, Sturegard E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schon T: Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. J Clin Microbiol 2010;48:1853-1858.
8. Heifets L, Lindholm-Levy P: Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against Mycobacterium avium and M. tuberculosis. Antimicrob Agents Chemother 1989;33:1298-1301.
9. Maus CE, Plikaytis BB, Shinnick TM: Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2005;49:3192-3197.
10. Via LE, Cho SN, Hwang S, Bang H, Park SK, Kang HS, Jeon D, Min SY, Oh T, Kim Y, Kim YM, Rajan V, Wong SY, Shamputa IC, Carroll M, Goldfeder L, Lee SA, Holland SM, Eum S, Lee H, Barry CE 3rd: Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean patients with drug-resistant tuberculosis. J Clin Microbiol 2010;48:402-411.
11. Handbook of anti-tuberculosis agents. Tuberculosis (Edinb) 2008;88:1-169.
12. Allen BW, Mitchison DA, Chan YC, Yew WW, Allan WG, Girling DJ: Amikacin in the treatment of pulmonary tuberculosis. Tubercle 1983;64:111-118.
13. Heifets L, Simon J, Pham V: Capreomycin is active against non-replicating M. tuberculosis. Ann Clin Microbiol Antimicrob 2005;4:6.
14. Duggal P, Sarkar M: Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term followup. BMC Ear Nose Throat Disord 2007;7:5.
15. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D: Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis 2004;38:1538-1544.
16. De Jager P, van Altena R: Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis 2002;6:622-627.
17. Bardien S, de Jong G, Schaaf HS, Harris T, Fagan J, Petersen L: Aminoglycoside-induced hearing loss: South Africans at risk. S Afr Med J 2009;99:440-441.
18. Sha SH, Qiu JH, Schacht J: Aspirin to prevent gentamicin-induced hearing loss. N Engl J Med 2006;354:1856-1857.
19. Luft FC, Bloch R, Sloan RS, Yum MN, Costello R, Maxwell DR: Comparative nephrotoxicity of aminoglycoside antibiotics in rats. J Infect Dis 1978;138:541-545.
20. Rieder HL: Interventions for Tuberculosis Control and Elimination. Paris, International Union against Tuberculosis and Lung Disease, 2002.
21. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, Wilson T, Collins D, de Lisle G, Jacobs WR Jr: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994;263:227-230.
22. Schaaf HS, Victor TC, Venter A, Brittle W, Jordaan AM, Hesseling AC, Marais BJ, van Helden PD, Donald PR: Ethionamide cross-and co-resistance in children with isoniazid-resistant tuberculosis. Int J Tuberc Lung Dis 2009;13:1355-1359.
23. Rastogi N, Labrousse V, Goh KS: In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996;33:167-175.
24. Auclair B, Nix DE, Adam RD, James GT, Peloquin CA: Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids. Antimicrob Agents Chemother 2001;45:810-814.
25. Dover LG, Corsino PE, Daniels IR, Cocklin SL, Tatituri V, Besra GS, Futterer K: Crystal structure of the TetR/CamR family repressor Mycobacterium tuberculosis EthR implicated in ethionamide resistance. J Mol Biol 2004;340:1095-1105.
26. Eule H: Ethionamide concentration in the blood and urine of healthy persons and lung patients (in German). Beitr Klin Erforsch Tuberk Lungenkr 1965;132:339-342.
27. Zhu M, Namdar R, Stambaugh JJ, Starke JR, Bulpitt AE, Berning SE, Peloquin CA: Population pharmacokinetics of ethionamide in patients with tuberculosis. Tuberculosis (Edinb) 2002;82:91-96.
28. Mattila MJ, Koskinen R, Takki S: Absorption of ethionamide and prothionamide in vitro and in vivo. Ann Med Intern Fenn 1968;57:75-79.
29. Heifets L: Qualitative and quantitative drugsusceptibility tests in mycobacteriology. Am Rev Respir Dis 1988;137:1217-1222.
30. Conte JE Jr, Golden JA, McQuitty M, Kipps J, Lin ET, Zurlinden E: Effects of AIDS and gender on steady-state plasma and intrapulmonary ethionamide concentrations. Antimicrob Agents Chemother 2000;44:1337-1341.
31. Hughes IE, Smith H: Ethionamide: its passage into the cerebrospinal fluid in man. Lancet 1962;1:616-617.
32. Henderson MC, Siddens LK, Morre JT, Krueger SK, Williams DE: Metabolism of the antituberculosis drug ethionamide by mouse and human FMO1, FMO2 and FMO3 and mouse and human lung microsomes. Toxicol Appl Pharmacol 2008;233:420-427.
33. De Barber AE, Mdluli K, Bosman M, Bekker LG, Barry CE 3rd: Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2000;97:9677-9682.
34. Rusch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S: Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006;44:688-692.
35. A comparison of the toxicity of prothionamide and ethionamide: a report from the research committee of the British Tuberculosis Association. Tubercle 1968;49:125-135.
36. McDonnell ME, Braverman LE, Bernardo J: Hypothyroidism due to ethionamide. N Engl J Med 2005;352:2757-2759.
37. Hallbauer UM, Schaaf HS: Ethionamide induced hypothyroidism in children. S Afr J Epidemiol Infect, in press.
38. Schaaf HS, Donald PR: The epidemiology and management of drug-resistant tuberculosis in childhood; in Spiegelburg DD (ed): New Topics in Tuberculosis Research. New York, Nova Science Publishers, 2007, pp 71-102.
39. Duncan DK, Carr DT, Pfuetze KH, Power MH:Serum concentrations of para-aminosalicylic acid (PAS) produced by various forms of PAS. Dis Chest 1951;19:138-148.
40. Carstensen B: Para-aminosalicylic acid (PAS) in pulmonary and extrapulmonary tuberculosis. Am Rev Tuberc 1950;61:613-620.
41. Karlson AG, Pfuetze KH, Carr T, Feldman WH, Hinshaw HC: The effect of combined therapy with streptomycin, para-aminosalicylic acid and promin on the emergence of streptomycinresistant strains of tubercle bacilli; a preliminary report. Mayo Clin Proc 1949;24:85-88.
42. Peloquin CA, Berning SE, Huitt GA, Childs JM, Singleton MD, James GT: Once-daily and twicedaily dosing of p-aminosalicylic acid granules. Am J Respir Crit Care Med 1999;159:932-934.
43. Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE: Pharmacokinetics of paraaminosalicylic acid granules under four dosing conditions. Ann Pharmacother 2001;35:1332-1338.
44. Peloquin CA: Pharmacological issues in the treatment of tuberculosis. Ann NY Acad Sci 2001;953:157-164.
45. McIlleron H. Tuberculosis drug information; in Schaaf HS, Zumla A (eds): Tuberculosis: A Comprehensive Clinical Reference. London, Saunders Elsevier, 2009, pp 958-971.
46. Balint JA, Fraser R, Hanno MG: Radio-iodine measurements of thyroid function during and after PAS treatment of tuberculosis. Br Med J 1954;i:1234-1237.
47. Tsapis N, Bennett D, O'Driscoll K, Shea K, Lipp MM, Fu K, Clarke RW, Deaver D, Yamins D, Wright J, Peloquin CA, Weitz DA, Edwards DA:Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinb) 2003;83:379-385.
48. Zitkova L, Tousek J: Pharmacokinetics of cycloserine and terizidone: a comparative study. Chemotherapy 1974;20:18-28.
49. Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA: Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy 2001;21:891-897.
50. Galletti F: Tolerability of terizidone. Minerva Med 1991;82:477-481.
51. Weyer K: Annexure 2: DOTS-Plus for multidrug resistant tuberculosis patients in South Africa. Systematic evaluation of a standardised treatment regimen applied under tuberculosis control programme conditions. 2004. http://wwwsahealthinfoorg/tb/annexures1-4pdf (accessed October 30, 2010).
52. Kwon HM, Kim HK, Cho J, Hong YH, Nam H: Cycloserine-induced encephalopathy: evidence on brain MRI. Eur J Neurol 2008;15:e60-e61.
53. Walker WC, Murdoch JM: Cycloserine in the treatment of pulmonary tuberculosis: a report on toxicity. Tubercle 1957;38:297-302.
54. Akula SK, Aruna AS, Johnson JE, Anderson DS:Cycloserine-induced Stevens-Johnson syndrome in an AIDS patient with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 1997;1:187-190.
55. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-692.
56. Reddy VM, Nadadhur G, Daneluzzi D, O'Sullivan JF, Gangadharam PR: Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob Agents Chemother 1996;40:633-636.
57. Van Ingen J, Simons S, de Zwaan R, van der Laan T, Kamst-van Agterveld M, Boeree MJ, van Soolingen D: Comparative study on genotypic and phenotypic second-line drug resistance testing of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010;48:2749-2753.
58. Abate G, Miorner H, Ahmed O, Hoffner SE: Drug resistance in Mycobacterium tuberculosis strains isolated from re-treatment cases of pulmonary tuberculosis in Ethiopia: susceptibility to first-line and alternative drugs. Int J Tuberc Lung Dis 1998;2:580-584.
59. Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA: Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) 2004;84:365-373.
60. Adams LB, Sinha I, Franzblau SG, Krahenbuhl JL, Mehta RT: Effective treatment of acute and chronic murine tuberculosis with liposomeencapsulated clofazimine. Antimicrob Agents Chemother 1999;43:1638-1643.
61. Shen GH, Wu BD, Hu ST, Lin CF, Wu KM, Chen JH: High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria. Int J Antimicrob Agents 2010;35:400-404.
62. Barry VC, Conalty ML: The antimycobacterial activity of B 663. Lepr Rev 1965;36:3-7.
63. Vree TB, Dammers E, Exler PS: Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of coamoxiclav in healthy subjects. J Antimicrob Chemother 2003;51:373-378.
64. Cynamon MH, Palmer GS: In vitro activity of amoxicillin in combination with clavulanic acid against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1983;24:429-431.
65. Nadler JP, Berger J, Nord JA, Cofsky R, Saxena M: Amoxicillin-clavulanic acid for treating drugresistant Mycobacterium tuberculosis. Chest 1991;99:1025-1026.
66. Chambers HF, Moreau D, Yajko D, Miick C, Wagner C, Hackbarth C, Kocagoz S, Rosenberg E, Hadley WK, Nikaido H: Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob Agents Chemother 1995;39:2620-2624.
67. Segura C, Salvado M, Collado I, Chaves J, Coira A: Contribution of beta-lactamases to betalactam susceptibilities of susceptible and multidrug-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 1998;42:1524-1526.
68. Abate G, Miorner H: Susceptibility of multidrugresistant strains of Mycobacterium tuberculosis to amoxycillin in combination with clavulanic acid and ethambutol. J Antimicrob Chemother 1998;42:735-740.
69. Donald PR, Diacon AH: The early bactericidal activity of anti-tuberculosis drugs: a literature review. Tuberculosis (Edinb) 2008;88(suppl 1):S75-S83.
70. Gupta R, Lavollay M, Mainardi JL, Arthur M, Bishai WR, Lamichhane G: The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat Med 2010;16:466-469.
71. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS: Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 2009;323:1215-1218.
72. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN: Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 2008;134:187-192.
73. Fortun J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, de la Pedrosa EG, Gomez-Mampaso E, Moreno S: Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005;56:180-185.
74. Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, Shim TS: Daily 300 mg dose of linezolid for the treatment of intractable multidrugresistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009;64:388-391.
75. Yew WW, Leung CC: How should we treat 'difficult' multidrug-resistant tuberculosis? Chest 2009;135:587-588.
76. Richter E, Rusch-Gerdes S, Hillemann D: First linezolid-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2007;51:1534-1536.
77. Rodriguez JC, Cebrian L, Lopez M, Ruiz M, Jimenez I, Royo G: Mutant prevention concentration:comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis. J Antimicrob Chemother 2004;53:441-444.
78. Burkhardt O, Borner K, von der Hoh N, Koppe P, Pletz MW, Nord CE, Lode H: Single-and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. J Antimicrob Chemother 2002;50:707-712.
79. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS: Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrugresistant tuberculosis. J Antimicrob Chemother 2006;58:701-704.
80. Nam HS, Koh WJ, Kwon OJ, Cho SN, Shim TS:Daily half-dose linezolid for the treatment of intractable multidrug-resistant tuberculosis. Int J Antimicrob Agents 2009;33:92-93.
81. Luna-Herrera J, Reddy VM, Daneluzzi D, Gangadharam PR: Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995;39:2692-2695.
82. Truffot-Pernot C, Lounis N, Grosset JH, Ji B: Clarithromycin is inactive against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:2827-2828.
83. Andini N, Nash KA: Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob Agents Chemother 2006;50:2560-2562.
84. Cavalieri SJ, Biehle JR, Sanders WE Jr: Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:1542-1545.
85. Mor N, Esfandiari A: Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother 1997;41:2035-2036.
86. Bosne-David S, Barros V, Verde SC, Portugal C, David HL: Intrinsic resistance of Mycobacterium tuberculosis to clarithromycin is effectively reversed by subinhibitory concentrations of cell wall inhibitors. J Antimicrob Chemother 2000;46:391-395.
87. Gorzynski EA, Gutman SI, Allen W: Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin. Antimicrob Agents Chemother 1989;33:591-592.
88. Stoffels K, Traore H, Vanderbist F, Fauville-Dufaux M: The effect of combined tobramycinclarithromycin on Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis 2009;13:1041-1044.
89. Umubyeyi A, Rigouts L, Shamputa IC, Dediste A, Struelens M, Portaels F: Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda. Int J Infect Dis 2008;12:152-156.
90. Domagk G, Behnisch R, Mietzsch F, Schmidt H: On a new class of compounds effective in vitro against tubercle bacilli. Naturwissenschaften 1946;33:315.
91. Leowski J: Thioacetazone-a review. Indian J Chest Dis Allied Sci 1982;24:184-189.
92. East African Hospitals and British Medical Research Council: Comparative trial of isoniazid in combination with thiacetazone or a substituted diphenylthiourea (SU1906) or PAS in the treatment of acute pulmonary tuberculosis in East Africans. Tubercle 1960;41:399-423.
93. East African Hospitals and British Medical Research Council: Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa-third investigation:the effect of an initial streptomycin supplement. Tubercle 1966;47:1-32.
94. East African Hospitals and British Medical Research Council: Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa-fifth investigation:a co-operative study in East African hospitals, clinics and laboratories with the collaboration of the East African and British Medical Research Councils. Tubercle 1970;51:123-151.
95. Van Deun A, Aung KJ, Hamid Salim MA, Ali MA, Naha MS, Das PK, Hossain MA, Declercq E: Extension of the intensive phase reduces unfavourable outcomes with the 8-month thioacetazone regimen. Int J Tuberc Lung Dis 2006;10:1255-1261.
96. Nunn P, Kibuga D, Gathua S, Brindle R, Imalingat A, Wasunna K, Lucas S, Gilks C, Omwega M, Were J, McAdam K: Cutaneous hypersensitivity reactions due to thiacetazone in HIV-1 seropositive patients treated for tuberculosis. Lancet 1991;337:627-630.
97. Alahari A, Trivelli X, Guerardel Y, Dover LG, Besra GS, Sacchettini JC, Reynolds RC, Coxon GD, Kremer L: Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS One 2007;2:e1343.
98. Cavanagh P, McPherson K: The thiacetazone sensitivity of Mycobacterium tuberculosis. J Med Microbiol 1969;2:237-242.
99. Ellard GA, Dickinson JM, Gammon PT, Mitchison DA: Serum concentrations and antituberculosis activity of thiacetazone. Tubercle 1974;55:41-54.
100. Nunn P, Porter J, Winstanley P: Thiacetazone-avoid like poison or use with care? Trans R Soc Trop Med Hyg 1993;87:578-582.
101. Sen PK, Chatterjef R: Anti-TB drug regimens: an approach through pharmacotherapeutic basis. Ind J Tub 1981;28:191-199.
102. Peloquin CA, Nitta AT, Berning SE, Iseman MD, James GT: Pharmacokinetic evaluation of thiacetazone. Pharmacotherapy 1996;16:735-741.
103. Francois AA, Nishida CR, de Montellano PR, Phillips IR, Shephard EA: Human flavincontaining monooxygenase 2.1 catalyzes oxygenation of the antitubercular drugs thiacetazone and ethionamide. Drug Metab Dispos 2009;37:178-186.
104. Gupta SK, Bedi RS, Maini VK: Agranulocytosis due to thiacetazone. Ind J Tub 1983;30:146-148.
105. Chintu C, Luo C, Bhat G, Raviglione M, Dupont H, Zumla A: Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I. Arch Dis Child 1993;68:665-668.